Bridgeway Capital Management’s Aardvark Therapeutics AARD Stock Holding History
Bought
Maintained
Sold
Other funds holding AARD
Bridgeway Capital Management's AARD Position: Q3 2026 in Review
Bridgeway Capital Management reduced its Aardvark Therapeutics (AARD) stake by 1.7% in Q3 2026, selling an estimated $2.43K and leaving 23,602 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #1096.
Bridgeway Capital Management first reported a position in AARD in Q3 2025 and has held it in 5 quarters since. The position peaked at $354K in Q4 2025. 76 funds tracked by Wall St. Rank hold AARD as of Q3 2026.
- Bridgeway Capital Management held 23,602 shares of Aardvark Therapeutics worth $124K as of Q3 2026.
- Bridgeway Capital Management sold 398 Aardvark Therapeutics shares in Q3 2026, an estimated $2.43K.
- Aardvark Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #1096 holding.
- Bridgeway Capital Management first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 5 quarters since.
- Bridgeway Capital Management's Aardvark Therapeutics position peaked at $354K in Q4 2025.
- 76 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q3 2026.
Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.